- Home
- SOS vs EPIX Comparison
SOS vs EPIX Comparison
Compare SOS & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOS
- EPIX
- Stock Information
- Founded
- SOS 2004
- EPIX 2009
- Country
- SOS China
- EPIX Canada
- Employees
- SOS N/A
- EPIX N/A
- Industry
- SOS Finance: Consumer Services
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- SOS Finance
- EPIX Health Care
- Exchange
- SOS Nasdaq
- EPIX Nasdaq
- Market Cap
- SOS 10.7M
- EPIX 9.1M
- IPO Year
- SOS 2017
- EPIX N/A
- Fundamental
- Price
- SOS $2.00
- EPIX $0.21
- Analyst Decision
- SOS
- EPIX Hold
- Analyst Count
- SOS 0
- EPIX 3
- Target Price
- SOS N/A
- EPIX $2.00
- AVG Volume (30 Days)
- SOS 1.1M
- EPIX 15.7M
- Earning Date
- SOS 09-24-2025
- EPIX 08-13-2025
- Dividend Yield
- SOS N/A
- EPIX N/A
- EPS Growth
- SOS N/A
- EPIX N/A
- EPS
- SOS N/A
- EPIX N/A
- Revenue
- SOS $231,424,000.00
- EPIX N/A
- Revenue This Year
- SOS N/A
- EPIX N/A
- Revenue Next Year
- SOS N/A
- EPIX N/A
- P/E Ratio
- SOS N/A
- EPIX N/A
- Revenue Growth
- SOS 150.42
- EPIX N/A
- 52 Week Low
- SOS $1.18
- EPIX $0.19
- 52 Week High
- SOS $2.04
- EPIX $7.41
- Technical
- Relative Strength Index (RSI)
- SOS 40.87
- EPIX 8.14
- Support Level
- SOS $1.50
- EPIX $0.19
- Resistance Level
- SOS $1.95
- EPIX $0.21
- Average True Range (ATR)
- SOS 0.30
- EPIX 0.02
- MACD
- SOS 0.17
- EPIX 0.03
- Stochastic Oscillator
- SOS 64.71
- EPIX 28.49
About SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.